Isotechnika Pharma Inc IPHAF

RE: News out, It's a winner.

[labumba]

I didn't hear Randall mentioning a "better " partnership can happen after the head-to-head EU trial in the webcast....may be I missed...it doesn't make sense to have it after EU trial in my opinion although ISA still has enough cash to complete the EU trial. From what I heard is that the 24 week data at present is more than sufficant to bolster any suitors' offers and the ball in fact is in ISA's court as management is studying for the best direction for this drug development for our investor value. They are seriously consider a long term direction by being a partnership with an international Pharmaceutical company. I guess it is " less cash up front but better prospect for the drug in a long term " and less preferably with a regional company which would possibly offer more cash up front. I see it is imminent that a partnership deal will materialize any time before June at this stage of development. Blog brought up the question that if it is necessary to the head-to-head trial with Csa. Despite it is an European market for CsA, Ranall did mention the past CSa trial results were " bias " due to the fact that some patients took break during the trials. This also partly anwers my question that why they have proprosed 1.50mg/kg/bid in coming head-head EU trial. Besides using the Ralative Potency Ratio as a yardstick for dosing, the lower dose would prevent patients from taking breaks , therefore, the safety data profile would be objective in comparison. All in a person's opinion